PDF(Pubmed)
Abstract：
UNASSIGNED: Cancer of the nasopharynx has remarkable geographic and ethnic variation in incidence and outcomes globally. Recent advances in diagnostic and therapeutic technologies provide new opportunities for early detection and improved outcomes. This study aimed to determine the incidence, demographics, outcomes and time trends of cancer of the nasopharynx in Aotearoa New Zealand over the last 25 years.
UNASSIGNED: In a population-based, national registry cohort study of notifications of malignant neoplasms of the nasopharynx made to the New Zealand Cancer Registry between 1994 and 2018, age-specific and age-standardised incidence rates and survival outcomes were evaluated.
UNASSIGNED: 577 registrations of nasopharyngeal cancer from between 1994 and 2018 were analysed; median age at diagnosis 54 years; 72.4% male; 37.4% Asian, 24.3% New Zealand European, 25.3% Pacific peoples, 13.0% Māori. Age-standardised annual incidence remained low (<1/100,000 person-years) and stable from 1994 to 2018. Age-standardised incidence rates in Pacific peoples, Asian and Māori were 21 (95% CI 12.07-35.21)-, 17 (10.95-25.33)- and 4 (2.79-7.07)-fold higher, respectively, than New Zealand Europeans. Epstein-Barr virus-related morphologies predominated keratinising squamous cell carcinoma and not-otherwise-specified morphological subtypes. Ten-year overall survival rate for the cohort was 49.2% (95% CI 44.7-53.5). Older age at diagnosis (65-94 years), Māori or Pacific ethnicity, keratinising squamous cell carcinoma and distant disease were associated with shorter overall survival, whereas younger age at diagnosis (10-29 years), and Asian ethnicity were associated with longer survival.
UNASSIGNED: Aotearoa New Zealand has a distinct profile of nasopharyngeal cancer, with age, ethnicity and morphology among the main determinants of incidence and survival.
UNASSIGNED: None.
UNASSIGNED: In a population-based, national registry cohort study of notifications of malignant neoplasms of the nasopharynx made to the New Zealand Cancer Registry between 1994 and 2018, age-specific and age-standardised incidence rates and survival outcomes were evaluated.
UNASSIGNED: 577 registrations of nasopharyngeal cancer from between 1994 and 2018 were analysed; median age at diagnosis 54 years; 72.4% male; 37.4% Asian, 24.3% New Zealand European, 25.3% Pacific peoples, 13.0% Māori. Age-standardised annual incidence remained low (<1/100,000 person-years) and stable from 1994 to 2018. Age-standardised incidence rates in Pacific peoples, Asian and Māori were 21 (95% CI 12.07-35.21)-, 17 (10.95-25.33)- and 4 (2.79-7.07)-fold higher, respectively, than New Zealand Europeans. Epstein-Barr virus-related morphologies predominated keratinising squamous cell carcinoma and not-otherwise-specified morphological subtypes. Ten-year overall survival rate for the cohort was 49.2% (95% CI 44.7-53.5). Older age at diagnosis (65-94 years), Māori or Pacific ethnicity, keratinising squamous cell carcinoma and distant disease were associated with shorter overall survival, whereas younger age at diagnosis (10-29 years), and Asian ethnicity were associated with longer survival.
UNASSIGNED: Aotearoa New Zealand has a distinct profile of nasopharyngeal cancer, with age, ethnicity and morphology among the main determinants of incidence and survival.
UNASSIGNED: None.
摘要：
■鼻咽癌在全球范围内的发病率和结果具有显著的地理和种族差异。诊断和治疗技术的最新进展为早期检测和改善结果提供了新的机会。这项研究旨在确定发病率，人口统计，过去25年新西兰奥特罗亚鼻咽癌的结局和时间趋势。
■在基于人口的情况下，在1994年至2018年期间向新西兰癌症登记处提交的鼻咽部恶性肿瘤通知的国家登记队列研究中,评估了年龄特异性和年龄标准化的发病率和生存结局.
■分析了1994年至2018年的577例鼻咽癌注册；诊断时的中位年龄54岁；72.4％的男性；37.4％的亚洲人，24.3%新西兰欧洲,25.3%的太平洋居民，13.0%毛利人。从1994年到2018年，年龄标准化年发病率仍然很低（<1/100,000人年），并且保持稳定。太平洋人民的年龄标准化发病率，亚裔和毛利人为21（95％CI12.07-35.21）-，17（10.95-25.33）-和4（2.79-7.07）-倍高，分别,比新西兰的欧洲人。爱泼斯坦-巴尔病毒相关的形态以角化鳞状细胞癌为主，而非其他指定的形态亚型。该队列的10年总生存率为49.2%（95%CI44.7-53.5）。诊断时年龄较大（65-94岁），毛利人或太平洋族裔，角化鳞状细胞癌和远处病变与较短的总生存期相关，而诊断时年龄较小（10-29岁），亚洲种族与更长的生存期有关。
■Aotearoa新西兰有明显的鼻咽癌，随着年龄,种族和形态是发病率和生存率的主要决定因素。
■无。
■在基于人口的情况下，在1994年至2018年期间向新西兰癌症登记处提交的鼻咽部恶性肿瘤通知的国家登记队列研究中,评估了年龄特异性和年龄标准化的发病率和生存结局.
■分析了1994年至2018年的577例鼻咽癌注册；诊断时的中位年龄54岁；72.4％的男性；37.4％的亚洲人，24.3%新西兰欧洲,25.3%的太平洋居民，13.0%毛利人。从1994年到2018年，年龄标准化年发病率仍然很低（<1/100,000人年），并且保持稳定。太平洋人民的年龄标准化发病率，亚裔和毛利人为21（95％CI12.07-35.21）-，17（10.95-25.33）-和4（2.79-7.07）-倍高，分别,比新西兰的欧洲人。爱泼斯坦-巴尔病毒相关的形态以角化鳞状细胞癌为主，而非其他指定的形态亚型。该队列的10年总生存率为49.2%（95%CI44.7-53.5）。诊断时年龄较大（65-94岁），毛利人或太平洋族裔，角化鳞状细胞癌和远处病变与较短的总生存期相关，而诊断时年龄较小（10-29岁），亚洲种族与更长的生存期有关。
■Aotearoa新西兰有明显的鼻咽癌，随着年龄,种族和形态是发病率和生存率的主要决定因素。
■无。
